Filing Flows › Coya Therapeutics (COYA) › R&D spending
Coya Therapeutics (COYA) R&D spending by quarter
Coya Therapeutics' R&D spending was $5.0M in Q2 2026 (second quarter 2026), +23% from Q1 2026. Over the last 7 quarters it ranged from $1.9M (Q4 2024) to $5.2M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $5.0M | +23% | +37% |
| Q1 2026 | $4.1M | -17% | -21% |
| Q4 2025 | $4.9M | +69% | +155% |
| Q3 2025 | $2.9M | -20% | — |
| Q2 2025 | $3.7M | -30% | — |
| Q1 2025 | $5.2M | +169% | — |
| Q4 2024 | $1.9M | — | — |
Q2 2026 at a glance
Coya Therapeutics, Q2 2026: revenue $244K (+49% year over year), net loss $6.6M, operating cash flow −$7.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Coya Therapeutics' R&D spending?
Coya Therapeutics' R&D spending was $5.0M in Q2 2026 (second quarter 2026), +23% from Q1 2026.
How has Coya Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $1.9M (Q4 2024) to $5.2M (Q1 2025).